Summit Global Investments Takes Position in Guardant Health, Inc. (NASDAQ:GH)

Summit Global Investments purchased a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 20,609 shares of the company's stock, valued at approximately $630,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Intech Investment Management LLC purchased a new position in Guardant Health during the third quarter worth about $754,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Guardant Health in the third quarter valued at approximately $721,000. Cerity Partners LLC grew its holdings in Guardant Health by 54.6% during the third quarter. Cerity Partners LLC now owns 195,008 shares of the company's stock worth $4,473,000 after acquiring an additional 68,883 shares during the period. Advantage Alpha Capital Partners LP acquired a new position in Guardant Health during the third quarter worth $343,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Guardant Health by 6.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,986 shares of the company's stock worth $665,000 after acquiring an additional 1,844 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GH has been the subject of several recent analyst reports. Morgan Stanley raised their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research note on Thursday, March 6th. Barclays started coverage on Guardant Health in a report on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Canaccord Genuity Group upped their target price on Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a report on Monday, February 24th. Finally, Scotiabank lifted their price target on Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Twenty investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $48.95.

Remove Ads

Guardant Health Stock Down 1.5 %

Shares of GH stock traded down $0.69 on Thursday, reaching $45.15. 1,160,004 shares of the stock were exchanged, compared to its average volume of 2,138,393. The stock has a market cap of $5.57 billion, a P/E ratio of -12.68 and a beta of 1.50. The firm has a 50 day moving average of $44.37 and a two-hundred day moving average of $34.03. Guardant Health, Inc. has a 1-year low of $15.81 and a 1-year high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. On average, equities research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.